JUMPSEAT
AEROSPACE NEWS

Varda Space Industries Raises $251M for Space-Based Medicine

Key Takeaways
  • Varda Space Industries raised $251M in Series D funding.
  • The company aims to manufacture medicines in microgravity.
  • Varda's spacecraft serve as laboratories and manufacturing facilities in orbit.
  • The funding brings Varda's total to $598M, valuing the company at $1.6B.
Sign in to view key takeaways Get full access to in-depth analysis and key takeaways.
Sign In
Silver membership required Upgrade to Silver to access Key Takeaways.
Upgrade
Strategic Implications

Varda's investment may indicate growing interest in space-based manufacturing, which could enable new pharmaceutical formulations with improved stability or effectiveness. The company's success may depend on making its orbital factories economical and reliable, which could have significant implications for the pharmaceutical industry.

Sign in to view strategic implications Get full access to strategic analysis and expert insights.
Sign In
Silver membership required Upgrade to Silver to access Strategic Implications.
Upgrade

What Happened

El Segundo Startup Expands Orbital Factories for Pharmaceutical Production

Varda Space Industries, an El Segundo-based startup, has raised $251M in Series D funding to advance its ambitious plan to manufacture medicines in microgravity. The company’s compact spacecraft serve as laboratories and manufacturing facilities in orbit, processing pharmaceutical materials and returning the results to Earth. With this funding, Varda’s total investment reaches $598M, valuing the company at $1.6B. The startup plans to use the funding to increase its flight cadence, expand pharmaceutical partnerships, and move closer to delivering the first medicine manufactured in space for use by patients on Earth, as reported by dot.LA.

Source | Originally Published: October 2, 2026

Advertisement 728 × 90
JUMPSEAT
AEROSPACE NEWS
JUMPSEAT
AEROSPACE NEWS

Varda Space Industries Raises $251M for Space-Based Medicine

Sponsored by: Jumpseat Solutions
Key Takeaways
  • Varda Space Industries raised $251M in Series D funding.
  • The company aims to manufacture medicines in microgravity.
  • Varda's spacecraft serve as laboratories and manufacturing facilities in orbit.
  • The funding brings Varda's total to $598M, valuing the company at $1.6B.
Sign in to view key takeaways Get full access to in-depth analysis and key takeaways.
Sign In
Silver membership required Upgrade to Silver to access Key Takeaways.
Upgrade
Strategic Implications

Varda's investment may indicate growing interest in space-based manufacturing, which could enable new pharmaceutical formulations with improved stability or effectiveness. The company's success may depend on making its orbital factories economical and reliable, which could have significant implications for the pharmaceutical industry.

Sign in to view strategic implications Get full access to strategic analysis and expert insights.
Sign In
Silver membership required Upgrade to Silver to access Strategic Implications.
Upgrade

What Happened

El Segundo Startup Expands Orbital Factories for Pharmaceutical Production

Varda Space Industries, an El Segundo-based startup, has raised $251M in Series D funding to advance its ambitious plan to manufacture medicines in microgravity. The company’s compact spacecraft serve as laboratories and manufacturing facilities in orbit, processing pharmaceutical materials and returning the results to Earth. With this funding, Varda’s total investment reaches $598M, valuing the company at $1.6B. The startup plans to use the funding to increase its flight cadence, expand pharmaceutical partnerships, and move closer to delivering the first medicine manufactured in space for use by patients on Earth, as reported by dot.LA.

Source | Originally Published: October 2, 2026

Advertisement 300 × 250 Google AdSense